Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Lu177-PSMA therapy in castration-resistant metastatic prostate cancer
IRCT20180113038331N1Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Dec 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177-PSMA in castration-resistant prostate cancer (CRPC), sponsored by Mashhad University of Medical Sciences. Primary endpoints: PSA level, progression-free survival and 2 more. Started Dec 2017; status: completed.
02
Drugs
lutetium Lu 177-PSMA
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on IRCT20180113038331N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180113038331N1.